Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-214 + Nivolumab in Advanced Solid Tumors (Japan)
NCT03745807Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bempegaldesleukin in solid tumor, sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events (AEs), Incidence of serious adverse events (SAEs) and 4 more. Started Apr 2019; status: completed.
02
Drugs
bempegaldesleukin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03745807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745807.